PureTech launches new biotech built around lung disease drug
The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for idiopathic pulmonary fibrosis.
Previous Post
How Wireless Handheld Ultrasound Devices Are Changing Point-of-Care Diagnostics
Next Post
Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago